Your session is about to expire
← Back to Search
Tivozanib for Liver Cancer (DEDUCTIVE Trial)
DEDUCTIVE Trial Summary
This trial will study whether the combination of tivozanib and durvalumab is safe and tolerated in people with advanced HCC, as well as whether the combination has preliminary anti-tumor activity.
- Liver Cancer
DEDUCTIVE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDEDUCTIVE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 277 Patients • NCT01076010DEDUCTIVE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What areas are hosting this clinical research?
"There are currently 12 clinical trial sites participating in this study, located in Seattle, Tyler and Orange. Patients should select the closest location to them to reduce travel burden if they decide to enrol."
How many participants are being admitted to this experiment?
"Unfortunately, recruitment for this trial is no longer ongoing. It was initially posted on September 30th 2019 and last updated November 17th 2022. However, there are currently 2608 studies enrolling patients with carcinoma hepatocellular and 336 trials recruiting participants to investigate Tivozanib's efficacy."
Are there vacancies in this investigation for potential participants?
"Unfortunately, this clinical trial is no longer recruiting individuals. The initial posting date was September 30th 2019 and the last edit happened on November 17th 2022. Other trials actively seeking patients with carcinoma and hepatocellular diseases are available; 2608 studies in total, while there are 336 studies searching for participants to take Tivozanib."
Have there been other experiments involving Tivozanib?
"Initially studied in 2010, tivozanib has been subject to 128 clinical trials. Currently there are 336 active studies, with a significant presence in Seattle, Washington."
What maladies can Tivozanib effectively combat?
"Physicians regularly administer Tivozanib to those undergoing neoadjuvant systemic therapy. Additionally, the drug can be beneficial in treating KRN 951, renal cell carcinoma, and various advanced directives."
Share this study with friends
Copy Link
Messenger